GlaxoSmithKline plc (GSK) is a global biopharmaceutical company headquartered in the United Kingdom. The company researches, develops, manufactures, and markets vaccines and specialty medicines, with core areas including infectious diseases, HIV (through majority-owned ViiV Healthcare), respiratory and immunology, and oncology. GSK operates extensive R&D programs and clinical development activities supported by a worldwide network of laboratories and regulatory engagements. In 2022, it demerged its consumer healthcare business into Haleon, focusing GSK on prescription medicines and vaccines.
For the chemical and life sciences value chain, GSK’s operations span small-molecule synthesis, biologics, and large-scale vaccine production, encompassing active pharmaceutical ingredient (API) and intermediate manufacturing for its own products, formulation, and fill-finish capabilities. The company maintains global manufacturing sites and supply chains adhering to GMP and other international quality standards, and collaborates with partners and institutions to advance new therapies and improve production reliability.
Also known as GlaxoSmithKline.
chemXplore tracks 4 projects involving GSK, of which one is active.
GSK's role on them: Owner, Investor / Financier, Operator, Developer, and Offtaker.
1 new construction.
Offtakers are recorded on this project For subscribers
Trispecific TCE binds T cells and two tumour antigens; entering Phase I in 2027; deal worth up to $750 million; designed to improve efficacy and tolerability versus current TCEs.
Phase I/II ARROS‑1 data show 94% ORR, 90% progression‑free at 12 months and strong intracranial activity; supplemental US submission planned for 2026.
Ris‑Rez extended median OS to 18.5 vs 10.3 months (HR 0.46) and showed improved PFS, response rates and fewer grade ≥3 TRAEs versus topotecan.
Ready-to-use syringe replaces two-vial format, simplifying administration for clinicians; approval based on technical comparability and keeps same indication and dosing.
Phase II showed higher immune responses vs licensed comparators and acceptable safety; phase III starts Sept 2026 with Fast Track FDA status.
Japan approves the first functional cure for chronic hepatitis B: 6‑month ASO therapy yields 19% functional cure in patients with HBsAg ≤3000 IU/ml; approval fast‑tracked by SENKU.
FDA sets PDUFA Feb 2027 for Jemperli’s supplemental filing based on AZUR‑1 data showing sustained 12‑month complete responses, potentially avoiding chemo, radiation and surgery.
Partner will lead clinical development, manufacturing and global commercialization of AID351, an anti‑dengue antibody active across four serotypes; originators retain royalty and sublicence share.
By country, the most active first. active / all projects
